Endocrine Abstracts

JOINT3859

Introduction: Primary hyperparathyroidism is a common condition associated with various complications, particularly cardiovascular ones. These complications are not widely studied, and further research is needed to better determine their prevalence. The objective of this study is to assess the cardiovascular impact of primary hyperparathyroidism in our series.

Objective: The aim of our study was to assess cardiovascular complications in patients with primary hyperparathyroidism.

Materials and Methods: A retrospective descriptive study including 40 patients followed for primary hyperparathyroidism over a 6-year period from 2018 to 2024.

Results: The mean age was 50 ± 10 years, with a male-to-female ratio of 0.05, and 95% of the patients were women. The evaluation of cardiovascular impact in primary hyperparathyroidism revealed electrocardiographic signs of hypercalcemia in 12.5% of patients, as well as newly diagnosed hypertension with a normal echocardiography, without valvular or myocardial calcifications, in 22.5% of patients. Notably, no cases of pulmonary embolism or peripheral venous thrombosis were observed in our study population.

Conclusion: Primary hyperparathyroidism is known for its cardiovascular complications, which are linked both to the direct effects of parathyroid hormone (PTH) as a hormone with cardiovascular properties and to the impact of hypercalcemia. Consequently, PHPT contributes to the worsening of cardiovascular risk factors or their de novo occurrence, highlighting the importance of early screening and appropriate management.